NCT01851096View on ClinicalTrials.gov

Safety and Pharmacology Study of SNX-5422 in Subjects With Resistant Lung Adenocarcinoma

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

October 31, 2015

Study Completion Date

August 31, 2016

Conditions
Cancer
Interventions
DRUG

SNX-5422

Capsules dosed every other day in the morning starting at a dose of 50 mg/m2. Dose escalation based on safety. Subjects will also receive 150 mg erlotinib daily (in the afternoon).

Trial Locations (2)

10065

Memorial Sloan Kettering Cancer Center, New York

20007

Georgetown University Medical Center, Washington D.C.

All Listed Sponsors
lead

Esanex Inc.

INDUSTRY

NCT01851096 - Safety and Pharmacology Study of SNX-5422 in Subjects With Resistant Lung Adenocarcinoma | Biotech Hunter | Biotech Hunter